SG11201810658PA - Methods for treating heterotopic ossification - Google Patents

Methods for treating heterotopic ossification

Info

Publication number
SG11201810658PA
SG11201810658PA SG11201810658PA SG11201810658PA SG11201810658PA SG 11201810658P A SG11201810658P A SG 11201810658PA SG 11201810658P A SG11201810658P A SG 11201810658PA SG 11201810658P A SG11201810658P A SG 11201810658PA SG 11201810658P A SG11201810658P A SG 11201810658PA
Authority
SG
Singapore
Prior art keywords
international
west
co7d
quiescent
massachusetts
Prior art date
Application number
SG11201810658PA
Inventor
Clarissa Desjardins
Donna Roy Grogan
Jeffrey Neal Packman
Mark Harnett
Original Assignee
Clementia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clementia Pharmaceuticals Inc filed Critical Clementia Pharmaceuticals Inc
Publication of SG11201810658PA publication Critical patent/SG11201810658PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Abstract

FIGA FIG. 3B 13,090 0 16,000 14,000 WOO 0 10,000 8,000 8,000 E LOGO 1,009 nano( Placebo/ Untreated PVD .• Ouleicent PV0 PVC PVC Non-QL escentonly Quiescent/ Non-Quiescent Only 10/5 mg Non-Quiescent 2010 mg 11,01X1 16„000 0 2 E E E 4,16 1 7i me. 413 mrtv su 4 7 • 14 0 10,731mm , 212 Me 4 . 1-10 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 December 2017 (14.12.2017) WIPO I PCT (51) International Patent Classification: A61K 31/415 (2006.01) A61P 3/00 (2006.01) A61K 31/44 (2006.01) CO7D 213/30 (2006.01) A61K 31/519 (2006.01) CO7D 231/12 (2006.01) A61P 19/04 (2006.01) CO7D 487/04 (2006.01) (21) International Application Number: PCT/CA2017/050701 (22) International Filing Date: 08 June 2017 (08.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/347,381 08 June 2016 (08.06.2016) US (71) Applicant: CLEMENTIA PHARMACEUTICALS INC. [CA/CA]; Suite 550, 4150 Ste-Catherine Street West, Montreal, Quebec H3Z 2Y5, Canada. (CA). (72) Inventors: DESJARDINS, Clarissa; 118 Aberdeen, West- mount, Quebec H3Y 3A7 (CA). GROGAN, Donna Roy; 56 Dwight St., #2, Boston, Massachusetts 02118-3609 (US). PACKMAN, Jeffrey Neal; 240 Country Dr., West- on, Massachusetts 02493-1138 (US). HARNETT, Mark; 141 Whitman St., Stow, Massachusetts 01775 (US). (74) Agent: BERESKIN & PARR LLP/S.E.N.C.R.L., S.R.L.; 40th Floor, 40 King Street West, Toronto, Ontario M5H 3Y2 (CA). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) = (54) Title: METHODS FOR TREATING HETEROTOPIC OSSIFICATION (57) : The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare- ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva. ill~~~~~~~~ 011101tIIl DIDu IDIIIolDIDIIIIImiEl0II111111 0IIIIII (10) International Publication Number WO 2017/210792 Al W O 20 17 / 2107 9 2 Al
SG11201810658PA 2016-06-08 2017-06-08 Methods for treating heterotopic ossification SG11201810658PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662347381P 2016-06-08 2016-06-08
PCT/CA2017/050701 WO2017210792A1 (en) 2016-06-08 2017-06-08 Methods for treating heterotopic ossification

Publications (1)

Publication Number Publication Date
SG11201810658PA true SG11201810658PA (en) 2018-12-28

Family

ID=60578331

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810658PA SG11201810658PA (en) 2016-06-08 2017-06-08 Methods for treating heterotopic ossification

Country Status (17)

Country Link
US (3) US10864194B2 (en)
EP (2) EP3468554B1 (en)
JP (2) JP7023868B2 (en)
KR (1) KR102486607B1 (en)
CN (1) CN109562099A (en)
AU (2) AU2017276835B2 (en)
BR (1) BR112018075422A2 (en)
CA (1) CA3025854A1 (en)
CL (1) CL2018003502A1 (en)
EA (1) EA201892497A1 (en)
ES (1) ES2963348T3 (en)
IL (2) IL295440A (en)
MX (2) MX2018015108A (en)
PH (1) PH12018502563A1 (en)
SG (1) SG11201810658PA (en)
WO (1) WO2017210792A1 (en)
ZA (1) ZA201808102B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX361414B (en) 2010-09-01 2018-12-05 Univ Jefferson Composition and method for muscle repair and regeneration.
KR102486607B1 (en) * 2016-06-08 2023-01-11 클레멘티아 파마슈티컬즈, 인크. How to treat heterotopic ossification
SG10202105186XA (en) 2016-11-16 2021-06-29 Clementia Pharmaceuticals Inc Methods for treating multiple osteochondroma (mo)
WO2020118405A1 (en) * 2018-12-13 2020-06-18 Clementia Pharmaceuticals Inc. Methods for treating heterotopic ossification
WO2021249240A1 (en) * 2020-06-11 2021-12-16 养生堂有限公司 Use of palovarotene in treatment against hbv virus

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US20030125252A1 (en) 2000-03-14 2003-07-03 Underhill T. Michael Compositions and methods for affecting osteogenesis
JP4118675B2 (en) 2000-10-02 2008-07-16 エフ．ホフマン−ラ ロシュ アーゲー A new retinoid for the treatment of emphysema
JP4410562B2 (en) 2001-09-18 2010-02-03 エフ．ホフマン−ラ ロシュ アーゲー Substituted urea retinoid agonist II
CN1283621C (en) 2001-09-18 2006-11-08 霍夫曼-拉罗奇有限公司 Alkyl urea vitamin A protagonist I
AUPR892501A0 (en) 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
JP2005206544A (en) 2004-01-23 2005-08-04 Yasuyoshi Uchida Muscle-regenerating agent
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
KR20070121758A (en) 2005-03-17 2007-12-27 엘란 파마 인터내셔널 리미티드 Injectable compositions of nanoparticulate immunosuppressive compounds
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
WO2007037188A1 (en) 2005-09-27 2007-04-05 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by increase in vasopermeability
KR20080089512A (en) * 2006-01-26 2008-10-06 콤비네이토릭스, 인코포레이티드 Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
MX2008012358A (en) 2006-03-31 2008-10-09 Hoffmann La Roche Process for preparing retinoid compounds.
ES2702128T3 (en) 2006-05-16 2019-02-27 Io Therapeutics Llc Antagonist or reverse RAR agonist for use in the treatment of side effects of chemotherapy and / or radiation therapy
WO2008055072A2 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
WO2009114180A1 (en) 2008-03-13 2009-09-17 The General Hospital Corporation Inhibitors of the bmp signaling pathway
EP2379174A4 (en) 2008-12-18 2012-11-14 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
US20120121546A1 (en) 2009-02-05 2012-05-17 Vishal Bhasin Method of Producing Progenitor Cells from Differentiated Cells
US20120277156A1 (en) * 2009-07-21 2012-11-01 University Of Washington Trhough It's Center For Commercialization Inhibition of pathological bone formation
MX361414B (en) 2010-09-01 2018-12-05 Univ Jefferson Composition and method for muscle repair and regeneration.
WO2012047674A2 (en) 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
US10485780B2 (en) 2011-03-14 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of proliferative disorders
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
EP2726084A1 (en) * 2011-07-01 2014-05-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Method of treating pathologic heterotopic ossification
KR102083041B1 (en) 2012-02-22 2020-05-27 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 Sulfonamide compounds and uses as tnap inhibitors
US9738636B2 (en) 2012-09-28 2017-08-22 Vanderbilt University Fused heterocyclic compounds as selective BMP inhibitors
MX363111B (en) 2012-11-08 2019-03-08 Univ Yamaguchi Therapeutic agent for keratoconjunctive disorders.
US20160115167A1 (en) * 2013-03-04 2016-04-28 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
JP6542192B2 (en) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． BMP inhibitors and methods of use thereof
CA2913005C (en) 2013-05-22 2021-08-10 Yamaguchi University Inhibitor for retinochoroidal disorders
US20170305883A1 (en) * 2014-10-01 2017-10-26 The Brigham And Women's Hospital, Inc. Compositions and Methods for Inhibiting BMP
US20180311356A1 (en) 2015-10-19 2018-11-01 The Children's Medical Center Corporation Method to inhibit endothelial-to-mesenchymal transition
EP3393474B1 (en) * 2015-12-24 2023-07-19 The Regents of The University of Michigan Method of treating heterotopic ossification
KR102486607B1 (en) * 2016-06-08 2023-01-11 클레멘티아 파마슈티컬즈, 인크. How to treat heterotopic ossification

Also Published As

Publication number Publication date
IL295440A (en) 2022-10-01
CA3025854A1 (en) 2017-12-14
WO2017210792A1 (en) 2017-12-14
JP7023868B2 (en) 2022-02-22
ES2963348T3 (en) 2024-03-26
EP4249490A3 (en) 2023-12-13
CL2018003502A1 (en) 2019-04-26
US20210069152A1 (en) 2021-03-11
CN109562099A (en) 2019-04-02
PH12018502563A1 (en) 2019-10-14
EP4249490A2 (en) 2023-09-27
AU2017276835B2 (en) 2022-03-31
IL263440B (en) 2022-09-01
AU2017276835A1 (en) 2018-12-13
BR112018075422A2 (en) 2019-03-12
US10864194B2 (en) 2020-12-15
IL263440A (en) 2019-01-31
EA201892497A1 (en) 2019-05-31
US20230285360A1 (en) 2023-09-14
AU2022202148B2 (en) 2023-08-24
KR20190017883A (en) 2019-02-20
MX2022001991A (en) 2022-03-11
EP3468554A1 (en) 2019-04-17
EP3468554C0 (en) 2023-08-09
EP3468554A4 (en) 2020-01-22
JP2022019995A (en) 2022-01-27
JP2019517528A (en) 2019-06-24
MX2018015108A (en) 2019-08-29
US20190216781A1 (en) 2019-07-18
AU2022202148A1 (en) 2022-04-21
EP3468554B1 (en) 2023-08-09
KR102486607B1 (en) 2023-01-11
US11622959B2 (en) 2023-04-11
ZA201808102B (en) 2024-04-24

Similar Documents

Publication Publication Date Title
SG11201810658PA (en) Methods for treating heterotopic ossification
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201902938TA (en) Compounds, devices, and uses thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201908517XA (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists
SG11201805950UA (en) Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201806401YA (en) G protein-coupled receptor (gpcr) modulation by imipridones
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof